Peritoneal Carcinomatosis: A Multidisciplinary Approach

Cover......Page 1
Half-Title......Page 2
Inside cover......Page 3
Copyright......Page 4
Foreword......Page 5
Preface......Page 7
Contents......Page 9
List of Contributors......Page 21
1. Structure and Function of Mesothelial Cells......Page 32
2. Molecular Biology of Peritoneal Carcinomatosis......Page 51
3. Role of Adhesion Molecules in Locoregional Cancer Spread......Page 64
4. Surgical Trauma, Minimal Residual Disease and Locoregional Cancer Recurrence......Page 79
5. Pseudomyxoma Peritonei Syndrome: Classification of Appendiceal Mucinous Tumours......Page 98
6. The Pathogenesis of Malignant Ascites......Page 135
7. Natural History of Peritoneal Carcinomatosisfrom Digestive Origin......Page 145
8. Intraperitoneal Drug Therapy: Physical and Biological Principles......Page 156
9. Current Status of Intraperitoneal Antineoplastic Drug Delivery......Page 178
10. The Biologic Rationale of Hyperthermia......Page 195
11. Interactions between Hyperthermia and Cytotoxic Drugs......Page 209
12. Pharmacodynamic Aspects of Intraperitoneal Cytotoxic Therapy......Page 218
13. Patient Selection for Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion......Page 238
14. Staging and Scoring of Peritoneal Carcinomatosis......Page 253
15. Peritonectomy Procedures......Page 269
16. Continuous Peritoneal Perfusion: Techniques, Methods and Applications......Page 287
17. Handling of Chemotherapeutic Drugs in the OR: Hazards and Safety Considerations......Page 296
18. Results of Cytoreduction followed by HIPEC in Carcinomatosis of Colorectal Origin......Page 312
19. HIPEC with Oxaliplatin in the Treatment of Peritoneal Carcinomatosis of Colorectal Origin......Page 323
20. Clinical Results of Cytoreduction and HIPEC in Pseudomyxoma Peritonei......Page 339
21. The Impact of Therapy in the Treatment of Pseudomyxoma Peritonei......Page 349
22. Clinical Results of Cytoreduction and HIPEC for Malignant Peritoneal Mesothelioma......Page 363
23. Cytoreduction and Intraperitoneal Chemotherapy for Carcinomatosis from Gastric Cancer......Page 376
24. Cytoreduction and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Cancer......Page 393
25. The role of Neoadjuvant Chemotherapy versus Primary Surgery in the Management of Stage III Ovarian Cancer......Page 404
26. Morbidity and Quality of Life following Cytoreduction and HIPEC......Page 420
27. Detection and Treatment of Recurrent Disease after Cytoreduction and HIPEC......Page 436
28. Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer......Page 442
29. Systemic Chemotherapy in patients with Peritoneal Carcinomatosis from Non Colorectal Origin......Page 458
30. The Role of Radiotherapy in the treatment of Peritoneal Carcinomatosis......Page 466
31. Medical and Palliative Management of Malignant Ascites......Page 475
32. Targeted Intraabdominal Chemotherapy for Peritoneal Carcinomatosis......Page 484
33. Immunotherapy of Peritoneal Carcinomatosis......Page 498
34. Intraperitoneal Photodynamic Therapy......Page 507
35. Intraperitoneal Gene Therapy......Page 529
Index......Page 539
Series Titles......Page 548